Palatin Technologies (PTN) Accumulated Depreciation (2013 - 2025)
Palatin Technologies' (PTN) quarterly Accumulated Depreciation came in at $3.5 million in Q2 2025, up 7.95% YoY from $3.3 million in Q2 2024, and up 7.95% on a QoQ basis from $3.3 million in Q2 2024.
Palatin Technologies (PTN) Accumulated Depreciation (2013 - 2025) Analysis & Trends
Palatin Technologies (PTN) has 4 years of Accumulated Depreciation data on file, last reported at $3.5 million in Q2 2025.
- Quarterly Accumulated Depreciation rose 7.95% year-over-year to $3.5 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $3.5 million (up 7.95% YoY) and the FY2025 annual result came in at $3.5 million, up 7.95% from the prior year.
- Accumulated Depreciation grew to $3.5 million in Q2 2025, from $3.3 million in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $3.5 million in Q2 2025 to a low of $3.3 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 3.52 Mn |
| Jun 30, 2024 | 3.26 Mn |
| Jun 30, 2014 | -2.09 Mn |
| Jun 30, 2013 | -1.98 Mn |